Building evidence on digital psychotherapies for adults living with depression: a systematic scoping review of populations, interventions and design features of ongoing and planned randomised controlled trials - Report - MDSpire

Building evidence on digital psychotherapies for adults living with depression: a systematic scoping review of populations, interventions and design features of ongoing and planned randomised controlled trials

  • By

  • Etienne Karl Duranté

  • Christopher James Veal

  • Blandine Thibout

  • Victoire Maçon-Dauxerre

  • Philippe Ravaud

  • Astrid Chevance

  • June 23, 2026

  • 0 min

Share

Clinical Report: Assessing the Landscape of Digital Psychotherapy Trials for Adult Depression

Overview

This systematic scoping review evaluates 681 randomized controlled trials (RCTs) of digital psychotherapies for adult depression, revealing gaps in methodological quality and reporting. Key findings indicate a predominance of cognitive-behavioral therapy and a concentration of trials in high-income countries.

Background

Depression is a major global health issue, affecting approximately 330 million adults. Digital psychotherapies have emerged as a solution to improve access to treatment. Understanding the landscape of current trials is crucial for identifying gaps.

Data Highlights

FindingPercentage
Completed RCTs51.8%
Published Results34.1%
Prospectively Registered78.1%
Industry Funded8.5%
Multicentre RCTs23.1%
Human Support in Interventions44.2%
Chatbots Assessed4.6%
Waitlist Control Used21%
Open-label RCTs49.3%
Primary Outcome: PHQ-935.7%

Key Findings

  • 51.8% of RCTs were completed, with 34.1% publishing results.
  • 78.1% of trials were prospectively registered.
  • 64.6% of interventions were based on cognitive-behavioral therapy.
  • 61.5% of trials relied on self-reported symptoms for inclusion.
  • Suicidal ideation was an exclusion criterion in 61.8% of trials.
  • 44.2% of interventions included human support.

Clinical Implications

The findings indicate a need for improved transparency and reporting in digital psychotherapy trials.

Conclusion

This review highlights methodological weaknesses in digital psychotherapy trials.

Related Resources & Content

  1. NICE, Guidance, 2025 -- Digitally enabled therapies for adults with depression: early value assessment
  2. JAMA Internal Medicine, 2025 -- A Digital Depression Treatment Program for Adults Treated in Primary Care: A Randomized Clinical Trial
  3. npj Digital Medicine, 2025 -- Assessing Youth Mental Health Needs Through an Adaptive Digital Tool: Findings from a Cross-Sectional Analysis
  4. npj Digital Medicine, 2025 -- Digital mental health interventions in Chinese: a scoping review
  5. Frontiers in Psychiatry, 2026 -- Comparative efficacy of non-pharmacological therapies in adolescents with subthreshold depression: a systematic review and network meta-analysis
  6. npj Digital Medicine — The user experience of ambulatory assessment and mood monitoring in depression: a systematic review & meta-synthesis
  7. 1 Recommendations | Digitally enabled therapies for adults with depression: early value assessment | Guidance | NICE
  8. A Digital Depression Treatment Program for Adults Treated in Primary Care: A Randomized Clinical Trial | Trials | JAMA Internal Medicine | JAMA Network
  9. Transdiagnostic-focused apps for depression and anxiety: a meta-analysis | npj Digital Medicine

Original Source(s)

Building evidence on digital psychotherapies for adults living with depression: a systematic scoping review of populations, interventions and design features of ongoing and planned randomised controlled trials

  • by Etienne Karl Duranté, Christopher James Veal, Blandine Thibout, Victoire Maçon-Dauxerre, Philippe Ravaud, Astrid Chevance

  • June 23, 2026

Related Content

Applying Change Theory to Enhance the Response to Socioeconomic Needs in Mental Health Care Services

Bidirectional Association Between Premenstrual Disorders and Psychiatric Disorders

Urine Markers May Aid Psych Diagnosis

Genetically predicted urinary metabolite levels were associated with schizophrenia, bipolar disorder, attention-deficit/hyperactivity disorder, and anorexia nervosa in a Mendelian randomization analysis.